PYK2 related products and methods
AssigneesSugen, Inc., New York University
InventorsSima Lev, Joseph Schlessinger
Life of this patent
Estimating the term…
Abstract
The present invention features a method for treatment of an organism having a disease or condition characterized by an abnormality in a signal transduction pathway, wherein the signal transduction pathway includes a PYK2 protein. The invention also features methods for diagnosing such diseases and for screening for agents that will be useful in treating such diseases. The invention also features purified and/or isolated nucleic acid encoding a PYK2 protein.
Claims15
Isolated, purified, or enriched nucleic acid encoding a nucleic acid encoding PYK2 polypeptide.
A nucleic acid probe for the detection of nucleic acid encoding a PYK2 polypeptide in a sample.
Recombinant nucleic acid encoding a PYK2 polypeptide and a vector or a promoter effective to initiate transcription in a host cell.
Recombinant nucleic acid comprising a transcriptional region functional in a cell, a sequence complimentary to an RNA sequence encoding a PYK2 polypeptide and a transcriptional termination region functional in a cell.
An isolated, purified, recombinant, or enriched PYK2 polypeptide having a phosphorylation activity.
A purified antibody having specific binding affinity to a PYK2 polypeptide.
A hybridoma which produces an antibody having specific binding affinity to a PYK2 polypeptide.
A method of detecting a compound capable of binding to a PYK2 polypeptide comprising the steps of incubating said compound with said PYK2 polypeptide and detecting the presence of said compound bound to said PYK2 polypeptide.
A method of screening potential agents useful for treatment of a disease or condition characterized by an abnormality in a signal transduction pathway, wherein said signal transduction pathway includes an interaction between a PYK2 polypeptide and a natural binding partner, comprising the step of assaying said potential agents for those able to promote or disrupt said interaction as an indication of a useful said agent.
A method for diagnosis of a disease or condition characterized by an abnormality in a signal transduction pathway, wherein said signal transduction pathway includes an interaction between a PYK2 polypeptide and a natural binding partner, comprising the step of detecting the level of said interaction as an indication of said disease or condition.
A method for treatment of an organism having a disease or condition characterized by an abnormality in a signal transduction pathway, wherein said signal transduction pathway includes an interaction between a PYK2 polypeptide and a natural binding partner comprising the step of promoting or disrupting said interaction.
Dependencies are inferred from the claim text.